Cargando…

Safety and efficacy of durvalumab (MEDI4736) in various solid tumors

INTRODUCTION: The prominent immune checkpoint molecule, programmed cell death ligand-1 (PD-L1), is the object of increasing attention. Here, we report a meta-analysis investigating the safety and efficacy of durvalumab (MEDI4736), an inhibitor of PD-L1, in various solid tumors. METHODS: A systematic...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Hui, Shen, Kai, Zhu, Chenjing, Li, Qingfang, Zhao, Yunuo, Ma, Xuelei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6038862/
https://www.ncbi.nlm.nih.gov/pubmed/30013326
http://dx.doi.org/10.2147/DDDT.S162214
_version_ 1783338581252636672
author Yang, Hui
Shen, Kai
Zhu, Chenjing
Li, Qingfang
Zhao, Yunuo
Ma, Xuelei
author_facet Yang, Hui
Shen, Kai
Zhu, Chenjing
Li, Qingfang
Zhao, Yunuo
Ma, Xuelei
author_sort Yang, Hui
collection PubMed
description INTRODUCTION: The prominent immune checkpoint molecule, programmed cell death ligand-1 (PD-L1), is the object of increasing attention. Here, we report a meta-analysis investigating the safety and efficacy of durvalumab (MEDI4736), an inhibitor of PD-L1, in various solid tumors. METHODS: A systematic search of PubMed, Embase, and related articles was performed. Safety data were analyzed using Comprehensive Meta-Analysis software program version 2. Ultimately, 17 studies with 1,529 patients were included in our analysis. RESULTS: The major adverse events associated with durvalumab were pruritus and fatigue, while pruritus, increased alanine transaminase, and increased aspartate aminotransferase were common among patients treated with a combination of durvalumab and tremelimumab. Higher PD-L1 expression was associated with a superior objective response rate. CONCLUSION: Durvalumab is safe in patients with many solid cancers and, in combination with tremelimumab, it has a tolerable safety profile and is associated with improved prognosis. PD-L1 expression is a biomarker of the efficacy of durvalumab.
format Online
Article
Text
id pubmed-6038862
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-60388622018-07-16 Safety and efficacy of durvalumab (MEDI4736) in various solid tumors Yang, Hui Shen, Kai Zhu, Chenjing Li, Qingfang Zhao, Yunuo Ma, Xuelei Drug Des Devel Ther Original Research INTRODUCTION: The prominent immune checkpoint molecule, programmed cell death ligand-1 (PD-L1), is the object of increasing attention. Here, we report a meta-analysis investigating the safety and efficacy of durvalumab (MEDI4736), an inhibitor of PD-L1, in various solid tumors. METHODS: A systematic search of PubMed, Embase, and related articles was performed. Safety data were analyzed using Comprehensive Meta-Analysis software program version 2. Ultimately, 17 studies with 1,529 patients were included in our analysis. RESULTS: The major adverse events associated with durvalumab were pruritus and fatigue, while pruritus, increased alanine transaminase, and increased aspartate aminotransferase were common among patients treated with a combination of durvalumab and tremelimumab. Higher PD-L1 expression was associated with a superior objective response rate. CONCLUSION: Durvalumab is safe in patients with many solid cancers and, in combination with tremelimumab, it has a tolerable safety profile and is associated with improved prognosis. PD-L1 expression is a biomarker of the efficacy of durvalumab. Dove Medical Press 2018-07-06 /pmc/articles/PMC6038862/ /pubmed/30013326 http://dx.doi.org/10.2147/DDDT.S162214 Text en © 2018 Yang et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Yang, Hui
Shen, Kai
Zhu, Chenjing
Li, Qingfang
Zhao, Yunuo
Ma, Xuelei
Safety and efficacy of durvalumab (MEDI4736) in various solid tumors
title Safety and efficacy of durvalumab (MEDI4736) in various solid tumors
title_full Safety and efficacy of durvalumab (MEDI4736) in various solid tumors
title_fullStr Safety and efficacy of durvalumab (MEDI4736) in various solid tumors
title_full_unstemmed Safety and efficacy of durvalumab (MEDI4736) in various solid tumors
title_short Safety and efficacy of durvalumab (MEDI4736) in various solid tumors
title_sort safety and efficacy of durvalumab (medi4736) in various solid tumors
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6038862/
https://www.ncbi.nlm.nih.gov/pubmed/30013326
http://dx.doi.org/10.2147/DDDT.S162214
work_keys_str_mv AT yanghui safetyandefficacyofdurvalumabmedi4736invarioussolidtumors
AT shenkai safetyandefficacyofdurvalumabmedi4736invarioussolidtumors
AT zhuchenjing safetyandefficacyofdurvalumabmedi4736invarioussolidtumors
AT liqingfang safetyandefficacyofdurvalumabmedi4736invarioussolidtumors
AT zhaoyunuo safetyandefficacyofdurvalumabmedi4736invarioussolidtumors
AT maxuelei safetyandefficacyofdurvalumabmedi4736invarioussolidtumors